2025 Universal Registration Document

6. 2025 parent company financial statements

In 2025, the tax charge recognised by L’Oréal included a tax consolidation loss of €137.7 million, due mainly to the impact of the non-recurring levy on subsidiaries included in the tax consolidation group.

In 2024, the tax charge recognised by L’Oréal included a tax consolidation loss of €0.9 million.

Tax credits can be broken down as follows:

€ millions 31.12.2025 31.12.2024
Research tax credits

Research tax credits

31.12.2025

34.2

Research tax credits

31.12.2024

33.9

Tax credits on royalties under international tax treaties

Tax credits on royalties under international tax treaties

31.12.2025

51.5

Tax credits on royalties under international tax treaties

31.12.2024

49.9

Tax credits on dividends under international tax treaties

Tax credits on dividends under international tax treaties

31.12.2025

15.1

Tax credits on dividends under international tax treaties

31.12.2024

13.5

Other

Other

31.12.2025

12.1

Other

31.12.2024

20.5

TAX CREDITS TAX CREDITS

31.12.2025

112.9
TAX CREDITS

31.12.2024

117.8

Note 10 Increases or reductions in future tax liabilities

Increases or reductions in future tax liabilities
  31.12.2024 Changes 31.12.2025
€ millions Assets Liabilities Assets Liabilities Assets Liabilities
TEMPORARY DIFFERENCES            
Regulated provisions   3.5 0.7 0.8   3.6
Temporarily non-deductible charges 146.1   4.9 15.2 135.8  
Charges deducted (or revenue taxed) for tax purposes but not yet recognised   6.3 5.7     0.6
Temporarily non-taxable revenue            
DEDUCTIBLE ITEMS            
Tax losses, deferred items            
POTENTIALLY TAXABLE ITEMS            
Special reserve for long-term capital gains   137.0       137.0

These figures factor in the social contribution of 3.3% which is added to corporate income tax, both at normal and reduced rates.

Note 11 Research costs

Expenses booked for Research activities in 2025 totalled €1,374.3 million, compared with €1,356.9 million in 2024. They include personnel costs, outsourced scientific services and patent costs.